# Grail Type: Company (GRAL) Source: GetYourBrief — https://getyourbrief.com/entity/grail Canonical HTML page: https://getyourbrief.com/entity/grail ## Timeline - **2026-07-07**: Global Milestone Announcement — Gene Solutions issues press release detailing ASCO recognition, FDA designation, and IPO plans, marking a turning point for the company. - **2026-07**: FDA Breakthrough Device Designation — The U.S. FDA grants Breakthrough Device Designation to SPOT-MAS 10, acknowledging its potential to address unmet needs in cancer screening. - **2026-06**: ASCO Breakthrough 2026 — Gene Solutions presents interim real-world data from 84,145 asymptomatic individuals for SPOT-MAS 10 at the ASCO Breakthrough conference in Singapore. - **2026-03-22**: Market Outperformance — Grail shares end the week as a top performer in the healthcare sector, recouping major losses. - **2026-03-22**: Market Outperformance — Financial media highlights Grail as the week's top performer in the diagnostics sector. - **2026-03-21**: Market Outperformance — Grail shares surge as market sentiment shifts from bearish to bullish, leading the biotech sector gains. - **2026-03-20**: Volume Surge — Stock sees highest trading volume in six months as institutional buyers return. - **2026-03-18**: TD Cowen Upgrade — TD Cowen upgrades Grail to 'Buy,' arguing the market overreacted to the leadership change. - **2026-03-18**: TD Cowen Upgrade — Analysts upgrade Grail to 'Buy,' citing an oversold condition and strong core fundamentals. - **2026-03-18**: TD Cowen Upgrade — Analysts upgrade GRAL, calling the recent selloff a 'buying opportunity' and stabilizing the stock price. - **2026-03-16**: Market Low — GRAL stock hits a 52-week low amid heavy selling pressure. - **2026-03-13**: CEO Transition & Setback — CEO Bob Ragusa retires following reports of a clinical trial setback, causing a sharp drop in GRAL shares. - **2026-03-13**: CEO Transition — Bob Ragusa steps down as CEO following reports of a trial setback. - **2026-03-13**: Leadership & Trial Volatility — CEO Bob Ragusa announces retirement; reports surface regarding a setback in the NHS-Galleri clinical trial. - **2026-02-20**: Candel Public Offering — Candel Therapeutics prices $100M public offering at $5.45 per share. ## Recent coverage (7 stories, network-wide) ### FDA Breakthrough Designation for SPOT-MAS 10 Validates Asia-Led Liquid Biopsy Innovation 2026-07-22 05:21:09 · Sector: bio · Sentiment: Strongly positive · Impact: 6/10 · Sources: 3 Gene Solutions' AI-powered multi-cancer liquid biopsy test, SPOT-MAS 10, gains FDA Breakthrough Device Designation after real-world data on 84,145 Asian individuals, signaling a new era for precision oncology emerging from Asia. Full story: https://getbiobrief.com/story/gene-solutions-spot-mas-fda-breakthrough ### 84,145-Patient Study Propels Gene Solutions' SPOT-MAS 10 to Asian Cancer Screening Forefront 2026-07-22 05:19:29 · Sector: health · Sentiment: Strongly positive · Impact: 6/10 · Sources: 3 A massive real-world study and FDA Breakthrough Device Designation position SPOT-MAS 10 as a potential paradigm shift in multi-cancer screening across Asian healthcare systems, offering a non-invasive, population-validated tool to combat rising cancer burdens. Full story: https://gethealthbrief.com/story/gene-solutions-spot-mas-asian-cancer-screening ### Grail Rebounds: Why the Liquid Biopsy Pioneer Crushed the Market This Week 2026-03-22 12:13:15 · Sector: startups · Sentiment: Positive · Impact: 6/10 · Sources: 2 After a volatile start to March marked by a CEO transition and clinical trial setbacks, Grail (GRAL) shares staged a massive recovery this week. The rebound was fueled by a high-profile analyst upgrade and a market correction following what many saw as an overreaction to recent headwinds. Full story: https://getstartupbrief.com/story/grail-gral-stock-surge-march-2026-analysis ### Grail Shares Surge as Market Reassesses NHS Trial Setback and TD Cowen Upgrade 2026-03-22 12:13:11 · Sector: finance · Sentiment: Positive · Impact: 6/10 · Sources: 2 Grail (GRAL) shares outperformed the broader market this week, staging a dramatic recovery following a sharp selloff earlier in the month. Investor sentiment shifted after a key analyst upgrade and a reassessment of the long-term impact of a recent clinical trial setback. Full story: https://getfinancebrief.com/story/grail-gral-stock-rally-march-2026 ### Grail Shares Outperform Market as Analysts Reassess Galleri Potential 2026-03-22 12:11:37 · Sector: bio · Sentiment: Positive · Impact: 6/10 · Sources: 2 Grail (GRAL) shares staged a significant recovery this week, outperforming the broader market following a period of heavy selling. The rebound was driven by a high-profile analyst upgrade and a shift in investor sentiment regarding the company's multi-cancer early detection (MCED) platform. Full story: https://getbiobrief.com/story/grail-stock-rally-march-2026 ### Grail Shares Surge as Analysts Call Recent Selloff a "Buying Opportunity" 2026-03-22 12:10:34 · Sector: health · Sentiment: Positive · Impact: 6/10 · Sources: 2 Grail (GRAL) stock staged a major recovery this week, outperforming the broader market after a pivotal upgrade from TD Cowen. The rally marks a significant shift in investor sentiment following a volatile period triggered by a CEO transition and clinical trial concerns. Full story: https://gethealthbrief.com/story/grail-stock-recovery-analysis-march-2026 ### US Futures Rebound as Markets Await Pivotal Q4 GDP Growth Data 2026-02-20 12:42:09 · Sector: finance · Sentiment: Positive · Impact: 6/10 · Sources: 2 US equity futures signaled a positive open on Friday as investors shifted focus toward the release of fourth-quarter GDP figures. Following a lackluster Thursday session, the market is looking for confirmation of economic resilience while monitoring individual movers like Grail and Candel Therapeutics. Full story: https://getfinancebrief.com/story/us-futures-rebound-gdp-data-grail-candel --- This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.